13F Pro

SEC Form 4 reporting owner

Jarrett Jennifer

Jarrett Jennifer has filed 9 Form 4 transactions reported between December 16, 2025 and June 17, 2026, as a reporting owner of Zura Bio Ltd, Director of Sagimet Biosciences Inc., a reporting owner of Damora Therapeutics, Inc., a reporting owner of Syndax Pharmaceuticals Inc and Chief Operating Officer of Arcus Biosciences, Inc..

Name as filed: Jarrett Jennifer

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$467K
2 lines
Companies
5
with Form 4 filings
Latest transaction
Jun 17, 2026
transaction date

Roles and reported holdings

  • ZURAZura Bio Ltd
    Jun 17, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • SGMTSagimet Biosciences Inc.
    Jun 12, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • DMRADamora Therapeutics, Inc.
    Mar 30, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • SNDXSyndax Pharmaceuticals Inc
    Feb 4, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • RCUSArcus Biosciences, Inc.
    Dec 16, 2025 – Jan 23, 2026

    Chief Operating Officer

    Held directly193,024 sh as of Dec 17, 2025 · Form 4

    24 months: $467K sold

Transaction history

All 9 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 17, 2026ZURAGrant or awardCode A · direct51,000—Form 4
Jun 12, 2026SGMTDirectorGrant or awardCode A · direct39,567—Form 4
Mar 30, 2026DMRAGrant or awardCode A · direct1,500,000—Form 4
Mar 30, 2026DMRAGrant or awardCode A · direct500,000—Form 4
Feb 4, 2026SNDXGrant or awardCode A · direct24,000—Form 4
Jan 23, 2026RCUSChief Operating OfficerGrant or awardCode A · direct126,000—Form 4
Jan 23, 2026RCUSChief Operating OfficerGrant or awardCode A · direct31,000—Form 4
Dec 17, 2025RCUSChief Operating OfficerOpen-market saleCode S · directAlso reported by Jaen Juan C.9,983$221K@ $22.16Form 4
Dec 16, 2025RCUSChief Operating OfficerOpen-market saleCode S · directAlso reported by Jaen Juan C.11,225$246K@ $21.88Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.